secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-05-12T13:02:24+00:00
Accession:  0001835268-26-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma reports Q1 net loss $19.4M; Phase 2 studies on track, topline data mid-2026
--------------------------------------------------------------------------------

- Net loss $19.4M ($0.34 loss per share) vs $10.3M loss ($0.19 per share) in Q1 2025.
- Cash $46.0M as of March 31, 2026; expects funding into H2 2027.
- Phase 2 Seabreeze STAT asthma/COPD studies continuing after DMC review; topline data expected mid-2026.
- Completed $20.2M private placement led by Panacea Venture on March 31, 2026.
- R&D expense $15.0M (up from $6.6M) due to rademikibart development; license revenue $0.2M from Simcere agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/cntb-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer